Spotlight On... Bavarian Nordic launches MRSA vaccine effort with partner Evaxion; Merck's Gardasil vaccines grow to $1.9B in 2015 sales; Whooping cough booster protection fades, study says; and more...

Bavarian Nordic has agreed to partner with Evaxion Biotech to develop a vaccine against methicillin-resistant Staphylococcus aureus (MRSA). The pair will set out to create a vaccine based on Bavarian Nordic's MVA-BN vaccine platform and will utilize Evaxion's computer-based tech to discover novel antigens. According to a release, Evaxion has demonstrated "promising" preclinical results, and the MVA-BN-based candidate will be tested in further preclinical models; human testing could begin in 2019. The Technical University of Denmark will assist in the preclinical testing. More from FierceBiotechIT

> Merck's ($MRK) Gardasil and Gardasil 9 franchise brought in $1.9 billion in 2015, the drugmaker reported, a 10% increase from 2014. Release

> A study of 175,000 children in California shows that whooping cough booster protection begins to fade rapidly after one year. Report

> With 250 confirmed dengue cases since Oct. 29, 2015, the mayor of Hawaii's Big Island has declared a state of emergency. Report

> The Institut Pasteur Foundation in Dakar is establishing a plant to produce yellow fever vaccines for local use. Report

> A new offer to take Sinovac Biotech ($SVA) private has valued the Chinese vaccines company at $390 million, FiercePharmaAsia reported. News

> According to a new study, every dollar spent expanding vaccine use could lead to $44 in savings. Release

> Transgene's TG4010 vaccine plus chemo improved progression-free survival in advanced NSCLC patients compared to placebo plus chemotherapy. News

Suggested Articles

Having struck two COVID-19 vaccine supply deals already, EU officials are in discussions with Novavax, as well.

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

BioNTech expects a quick turnaround once the transaction closes and plans to produce up to 250 million doses of BNT162b2 in the first half of 2021.